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It has been suggested that the antipsychotic clozapine may 
modulate brain glutamate, and that this effect could contribute 
to its efficacy in treatment-resistant schizophrenia (TRS). The 
aim of this study was to examine the effects of clozapine on 
brain glutamate in TRS longitudinally. This study examined 
individuals with TRS before and 12 weeks after switching from 
a non-clozapine antipsychotic to treatment with clozapine as 
part of their normal clinical care. Proton magnetic resonance 
spectroscopy (1H-MRS) measured concentrations, corrected 
for voxel tissue content, of glutamate (Glucorr), and glutamate 
plus glutamine (Glxcorr) in the anterior cingulate cortex (ACC) 
and right caudate nucleus. Symptoms were monitored using 
the Positive and Negative Syndrome Scale (PANSS). Of 37 
recruited patients (27 men, 39.30  years old, 84% clozapine 
naïve), 25 completed 1H-MRS at both timepoints. 12 weeks 
of clozapine was associated with a longitudinal reduction in 
Glucorr in the caudate (n = 23, F = 7.61 P = .01) but not in 
the ACC (n = 24, F = 0.02, P = .59). Percentage reduction in 
caudate Glucorr was positively correlated with percentage im-
provement in symptoms (total PANSS score, n = 23, r = .42, 
P = .04). These findings indicate that reductions in glutamate 
in the caudate nucleus may contribute to symptomatic im-
provement during the first months of clozapine treatment.
Key words:  1H-MRS/magnetic resonance spectroscopy/a
ntipsychotic/anterior cingulate cortex/caudate/psychosis
Introduction
Clozapine is the only antipsychotic recommended for 
patients with treatment-resistant schizophrenia (TRS).1 
However, approximately half  of patients with TRS do 
not respond to clozapine.2,3 The neurobiological mechan-
isms that mediate clozapine response are unclear, and it is 
currently not possible to predict in advance whether clo-
zapine will be effective in improving symptoms.
Cross-sectional proton magnetic resonance spectros-
copy (1H-MRS) studies indicate that patients with TRS 
taking non-clozapine antipsychotics have higher levels 
of  glutamate in the anterior cingulate cortex (ACC) than 
patients with schizophrenia who have shown a good an-
tipsychotic response4 and healthy volunteers.5,6 Similarly, 
elevated ACC glutamate levels have been linked to a poor 
response to conventional antipsychotic treatment early 
in illness.7,8 In contrast, studies examining participants 
with TRS taking clozapine at the time of scanning have 
reported no difference in ACC glutamate or Glx (the 
combined signal from glutamate and glutamine) in com-
parison to an antipsychotic-responsive group.9,10 One 
explanation for this difference could be that clozapine 
treatment reduces ACC glutamate levels. Interestingly, 
binding to the NMDA receptor intrachannel PCP/
MK-801 site is reduced across the brain in clozapine-
treated, but not typical-antipsychotic-treated patients 
with schizophrenia relative to healthy volunteers, which 
may also indicate that clozapine modulates glutamatergic 
systems.11 It is also possible that a reduction in ACC glu-
tamate may relate to the degree of the clozapine response. 
In comparison to healthy volunteers, ACC Glx levels 
were elevated in clozapine-nonresponsive TRS (termed 
ultra-resistant schizophrenia, URS), but not in patients 
with TRS who had responded to clozapine.10
In addition to the ACC, schizophrenia is associated with 
glutamatergic elevation in the striatum.12 In first-episode 
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psychosis, effective treatment with risperidone reduces glu-
tamate in the right caudate (associative striatum) and this 
reduction correlates with improvement in symptoms.13 It is 
unknown whether effective clozapine treatment produces 
similar reductions in striatal glutamate. One cross-sec-
tional study including patients with TRS taking clozapine 
found higher Glx in the putamen compared to both an 
URS and an antipsychotic-responsive group,9 although no 
group difference was found in a similar study examining 
the caudate.10 Overall, while effective treatment with non-
clozapine antipsychotics may reduce glutamate or Glx in 
the ACC14–16 and striatum13 (and see17,18), it is possible that 
glutamate metabolites remain elevated in patients who are 
treatment-resistant. The effects of clozapine on glutamate 
in either the ACC or striatum have not been yet investi-
gated longitudinally in humans.
While 1H-MRS measures the total amount of intracel-
lular glutamate in the voxel and not that associated with 
neurotransmission specifically, effects of clozapine on 
glutamatergic neurotransmission have been described in 
preclinical research. In the rodent prefrontal cortex, clo-
zapine attenuates the increases in extracellular glutamate 
efflux19–21 and disruptions in neuronal firing22 that are 
stimulated by blocking N-methyl-D-aspartate (NMDA) 
receptors. In rodents, clozapine administration also de-
creases glutamate concentrations in ex vivo frontal cortex 
tissue samples,23,24 and may decrease the in vivo 1H-MRS 
glutamate signal in the rat striatum.25
Whilst the effects of clozapine on brain glutamate in 
schizophrenia have not been investigated before, clinical 
studies have examined the effect of clozapine on plasma 
or serum glutamate levels. These studies have reported in-
creases,26 decreases27 and no effect28,29 of clozapine adminis-
tration overall. However, a good response has recently been 
associated with higher serum glutamate levels relative to 
poor clozapine response.30 Nonetheless, the relationship be-
tween peripheral and central glutamate levels is unclear and 
the role of glutamate in the clozapine response can be more 
directly evaluated by using 1H-MRS to measure brain glu-
tamate levels in patients undergoing clozapine treatment.
The aim of this study was to measure glutamate levels 
in the ACC and striatum in patients with TRS before and 
12 weeks after switching from their current antipsychotic 
to treatment with clozapine. Our main hypothesis was 
that glutamate would be reduced in these 2 areas over the 
12-week observation period. In secondary analyses, we 
hypothesized that longitudinal reductions in glutamate 
concentration would be correlated with the degree of 
symptomatic improvement.
Methods
Participants and Clinical Measures
This study was approved by London South East NHS 
ethics committee (Ref:13/LO/1857). Participants were 
recruited from inpatient and outpatient services within 
the South London and Maudsley, and the Oxleas NHS 
Foundation Trusts.
The study included participants meeting ICD-10 cri-
teria for schizophrenia (F20) or schizoaffective disorder 
(F25), as diagnosed by their treating psychiatrist, who 
were due to switch from their current antipsychotic to 
clozapine as part of their normal clinical care. Inclusion 
required that participants were clozapine naïve or had not 
taken clozapine for at least 3 months prior to the study. 
The presence of TRS was inferred from medical records 
and from their treating psychiatrist. Criteria included at 
least 2 previous trials of a non-clozapine antipsychotic, 
each within the recommended dose range for at least 6 
weeks, a diagnosis of TRS provided by their psychiatrist 
and referral for clozapine initiation. Participants with 
mental capacity to consent provided written informed 
consent to study procedures. The study was also open to 
participants lacking capacity to consent if  a consultee 
advised assent on their behalf. The consultee was de-
fined as a person nonprofessionally involved in caring 
for the patient or concerned with their welfare (normally 
their next-of-kin family member). They were advised on 
the role of the consultee, provided with a consultee in-
formation sheet and invited to ask any questions about 
the study before advising on the patient’s behalf. If  there 
was any indication from the patient, consultee, clinical 
team, or anyone else involved in the patient’s care that 
the patient would not wish to participate, they were not 
enrolled in the study. During study participation, study 
researchers maintained contact with the consultee and 
clinical team. If  the patient expressed any objections to 
the study or wishes to withdraw, they were withdrawn 
from the study immediately. General exclusion criteria in-
cluded drug dependency, as defined in DSM-IV, or preg-
nancy. Participants with contraindications to magnetic 
resonance imaging (MRI) at 3 Tesla were excluded from 
MRI but were able to participate in the larger study, in-
cluding clinical assessment and blood sampling.
Clinical assessment and MRI/MRS were performed 
at baseline (−14 to 0 days before clozapine titration) and 
repeated 12 weeks after clozapine initiation. This period 
was selected as a 12-week treatment period has been as-
sociated with clozapine response in ~50% of patients.31,32 
Clozapine plasma levels were measured in blood samples 
taken at 6 and 12 weeks to evaluate whether clozapine 
levels were above the indicated therapeutic threshold of 
350 ng/ml,32 blood samples were also collected at 8 weeks 
if  below threshold at 6 weeks.
Demographic and clinical history was collected through 
self-report and review of medical records. Clinical as-
sessment instruments included the Positive and Negative 
Syndrome Scale (PANSS),33 Clinical Global Impression 
– Schizophrenia scale (CGI-S)34 Global Assessment 
of Functioning scale (GAF)35 and Personal and Social 
Performance scale (PSP).36 We assessed the percentage 
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using the formula: (12-week score – baseline score) / 
baseline score × 100, after subtracting minimum possible 
scores.37
Magnetic Resonance Imaging
MR data were acquired on a 3 Tesla MR750 scanner 
(General Electric) (supplementary methods). 1H-MRS 
spectrum were acquired in 8 cm3 (2 × 2 × 2 cm3) voxels 
prescribed in the bilateral ACC7,8 and in the right cau-
date nucleus13,38 (supplementary figure S1). Spectrum 
were acquired using a conventional PRESS (Point 
RESolved Spectroscopy) acquisition with 96 averages, 
TR = 3000 ms and with a TE = 30 ms in the ACC and a 
TE = 35 ms in the caudate.13
Data Processing
Spectrum were analyzed with LCModel version 6.3-0I 
(supplementary methods). Spectral quality was evalu-
ated by visual inspection, and individual metabolite es-
timates were excluded if  the Cramér Rao Lower Bound 
estimates of the standard deviations (%SD) were greater 
than >20%.
Metabolite values were corrected for voxel tissue con-
tent using the formula:
Mcorr = M ∗ (WM + 1.21 ∗ GM + 1.55 ∗ CSF) / (wm + gm) ,
where M is the uncorrected metabolite, and WM, GM 
and CSF indicate the fraction of white and gray matter 
and cerebrospinal fluid content in the voxel. The formula 
assumes a CSF water concentration of 55 556 mol/m3.39,40 
Voxel GM ratio was calculated as GM/(GM+WM).
Statistical Analysis
Analysis was performed in SPSS version 25, IBM. Data 
were inspected for normality of distribution and outlying 
values. Initial analysis identified any relationships be-
tween glutamatergic metabolite levels at baseline and the 
clinical and demographic characteristics of the sample 
using t-tests for categorical variables and Pearson’s cor-
relations for continuous variables (threshold P  =  .05). 
Where significant, the potential influences of these vari-
ables were subsequently investigated during hypothesis 
testing. For the main analysis, repeated measures analysis 
of variance examined the effects of 12 weeks of cloza-
pine treatment on Glucorr and Glxcorr levels in the ACC 
and caudate. In the main analysis, the threshold for statis-
tical significance was corrected for the 2 voxels examined 
(P  =  0.05/2  =  .025). In exploratory analysis, Pearson’s 
correlations investigated relationships between glutamate 
metabolite levels and PANSS Total scores, and between 
the percentage change in glutamate metabolites and 
PANSS scores over 12 weeks.
Results
Demographic and Clinical Characteristics of 
the Sample
Seventy-seven participants with TRS consented to the 
larger study, of whom 37 completed at least one MR ses-
sion (table 1). Common reasons for nonparticipation in 
MR included presence of MRI contraindication, being 
above the scanner weight limit, or being too unwell to 
leave the ward or tolerate the scanning session. Within 
patients in whom baseline PANSS scores were available, 
there was no significant difference in symptom severity 
between those who did or did not participate in MRI 
(mean ± SD PANSS total score: MRI: n = 37; 79.19 ± 
15.02; No MRI: n  =  24; 74.21  ± 19.44; t(59)  =  −0.46; 
P = .65). Twenty-five participants had complete data, in-
cluding 1H-MRS and PANSS scores at both baseline and 
12 weeks. A further 10 participants completed 1H-MRS 
at baseline (total baseline 1H-MRS = 35), of whom 7 sub-
sequently left the study, and 3 completed 12-week PANSS 
but not 12-week 1H-MRS. An additional 2 participants 
declined baseline 1H-MRS but completed all PANSS 
ratings and 12-week MRS (total 12-week 1H-MRS = 27). 
This resulted in PANSS ratings in a total of 37 patients at 
baseline, and 30 patients at 12 weeks. Reasons for drop-
out over the observation period (total n = 7), included not 
commencing clozapine (n  =  2), discontinuing clozapine 
due to poor tolerability or other medical concern (n = 4) 
or moving outside the participating NHS Trusts (n = 1). 
Concomitant use of GABA-acting (eg, benzodiazepines) 
and/or serotonergic (eg, selective serotonin reuptake in-
hibitor antidepressants) was relatively common (32% and 
51% of the sample, respectively, table 1), as were psychi-
atric comorbidities and previous substance use (table 1).
Symptom severity and functioning were improved after 
12 weeks of clozapine compared to baseline (table 2). At 
12 weeks, the mean plasma clozapine level was 0.46  ± 
0.28  ng/ml (supplementary table  1). The percentage 
change in PANSS total score was associated with cloza-
pine dose at 12 weeks (r = −.50, n = 30, P = .01), likely 
reflecting the prescription of higher doses to individuals 
showing less symptomatic improvement. The change in 
total PANSS score was not related to plasma clozapine 
level at 12 weeks (P > .05).
1H-MRS Spectral Quality
Of the 35 baseline 1H-MRS sessions, all ACC spectrum 
were included in the analyses, but Glu and Glx values 
were excluded in one caudate spectra due to CRLB > 
20%. Of the 27 12-week 1H-MRS sessions, CRLB > 20% 
led to exclusion of Glu and Glx in one ACC spectra and 
Glx but not Glu in one caudate spectra. At 12 weeks, 
ACC but not caudate spectrum were acquired in 2 par-
ticipants. This resulted in ACC glutamate values for 
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timepoints, and caudate glutamate values for 34 patients 
at baseline, 25 at 12 weeks, and 23 at both timepoints. All 
values for metabolites, spectral quality, and voxel tissue 
composition are presented in supplementary tables 2 and 
3. GM ratio of the ACC voxel was significantly lower 
at 12 weeks compared to at baseline. There were no sig-
nificant differences between timepoints in caudate voxel 
tissue composition (supplementary table 2).
Table 1. Demographic and Clinical Characteristics of the Total Sample
Age 39.30 ± 13.56
Sex (M / F) 27 / 10
Age of onset 25.51 ± 8.74
Duration of illness 15.08 ± 9.19
Previous antipsychotic trials (median; range; min; max) 3; 8; 2; 10
Previous clozapine trial (Y / N) 6 / 31
Number of hospitalizations (median; range; min; max) 3; 12; 0; 12
Capacity to consent (Y/N) 32 / 5
Diagnosis (F20 / F25) 30 / 7
Comorbid psychiatric diagnosis
 Affective disorder 6
 Anxiety disorder 1
 Epilepsy 1
 Personality disorder 1
 Post-traumatic stress disorder 1
 None 27










Antipsychotic dose at baseline mean ± SD CPZE/mg per day 219.41 ± 184.85
Antidepressant medication: N (Y / N) 12 / 25 
GABAergic medication: N (Y / N) 18/19
GABAergic medication: N (BDZ/Val/Li/Zop/PreG/Lam) 11/7/3/1/1/1
Current tobacco use N (Y / N) 15 / 22
Current alcohol current use N (Y / N) 10 / 27
Substance abuse ever N (Y / N) 25 / 12






 Legal Highs 5
 Inhalants 2
 Heroin 1
Current Substance use N, (Y / N) 7 / 30






 Legal Highs 0
 Inhalants 0
 Heroin 0
Note: Values are provided as mean ± SD unless otherwise stated. CGI-S, Clinical Global Impression- Schizophrenia; CPZE, Chlorprom-
azine equivalent dose; GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and 
Social Performance. Diagnosis, F20, Schizophrenia; F25, Schizoaffective disorder; CNS medication, 5-HT, serotonergic antidepressants 
(including citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, reboxetine, venlafaxine); GABA, GABAergic medica-
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Baseline Glutamate Metabolite Levels and Sample 
Characteristics
Baseline glutamate metabolite levels in the ACC and cau-
date were not associated with age, duration of illness, 
age at illness onset, sex, current smoking status, presence 
of GABAergic medication or voxel GM ratio (P > .05). 
Baseline ACC Glucorr was higher in clozapine naïve partici-
pants compared to those who had previously taken cloza-
pine (mean ± SD: ACC Glucorr naïve: 14.80 ± 2.11, n = 29; 
retrial: 12.62 ± 3.12, n = 6; t(33) = 2.12; P =  .04). ACC 
Glxcorr showed a similar effect of previous clozapine expo-
sure (naïve: 20.73 ± 3.82, n = 29; retrial: 16.13 ± 4.48, n = 6; 
t(33)  =  2.50; P  =  .02). The elevation in ACC glutamate 
metabolites in clozapine naïve compared to retrial partici-
pants remained significant when covarying for ACC GM 
ratio (Glucorr: F(32) = 4.29; P = .05; Glxcorr: F(32) = 5.85; 
P = .02). Caudate Glucorr did not differ between clozapine 
naïve and retrial participants (P > .6). Baseline ACC Glucorr 
was also higher in participants who reported drinking al-
cohol compared to those who did not (ACC Glucorr non-
alcohol drinkers 13.82  ± 2.18, n  =  26; alcohol drinkers: 
16.19 ± 2.26, n = 9; t(33) = 2.78; P = .01), including when 
covarying for ACC GM ratio (F(32) = 8.44; P = .01). This 
effect was present at trend-level for ACC Glxcorr (P = .08). 
Caudate Glucorr, was higher in participants prescribed anti-
depressants at baseline (Caudate Glucorr no antidepressant 
11.18 ± 1.98, n = 24; antidepressant: 14.23 ± 5.72, n = 10; 
t(32) = 2.34; P = .03), for caudate Glxcorr this effect had a 
significance value of P = .13.
Effect of 12-Week Clozapine on Glutamate Levels
In the ACC, there was no significant difference in Glucorr or 
Glxcorr at baseline compared to after 12 weeks of clozapine 
treatment (table 3, figure 1). This was also the case when anal-
ysis was restricted to participants who were clozapine naïve 
at baseline, or who did not drink alcohol, or when covarying 
for the numerical difference in voxel GM ratio over time, clo-
zapine dose, or plasma levels at 12 weeks (P > .05).
In the caudate, Glucorr was significantly reduced after 
12 weeks of clozapine treatment compared to at base-
line (table 3, figure 1). The reduction in caudate Glucorr 
remained significant when covarying for numerical dif-
ference in caudate voxel GM ratio over time (P = .005), 
antidepressant use at baseline (P  =  .02), clozapine 
dose (P  =  .05), or clozapine plasma levels at 12 weeks 
(P =  .003). Caudate Glxcorr showed a similar pattern of 
reduction over time, but this was not significant following 
multiple comparisons correction (table 3).
Relationships Between Glutamatergic Metabolites and 
Symptoms
The relationships between percentage change in ACC 
glutamate metabolites and percentage change in PANSS 
total score were nonsignificant (ACC Glucorr: n  =  24; 
r = −.36; P = .08; figure 2). In the caudate, there was a 
direct relationship, such that greater reductions in Glucorr, 
but not Glxcorr were associated with greater improvements 
in symptoms (n = 23, r = .42, P = .04), which was also 
significant when controlling for numerical difference in 
caudate GM ratio over time (P = .03). Relationships be-
tween baseline Glucorr and Glxcorr and total PANSS score 
at baseline or 12 weeks were nonsignificant.
Discussion
Although modulation of brain glutamate has been sug-
gested to contribute to the efficacy of clozapine, this has 
Table 2. Symptoms and Functioning at Baseline and 12 Weeks
Symptoms and Functioning
Baseline 12 Weeks  
Total sample (Baseline N = 37; 12 Weeks N = 30)
 PANSS—Positive 18.00 ± 5.87 13.57 ± 4.85  
 PANSS—Negative 19.22 ± 7.52 15.37 ± 6.20  
 PANSS—General 35.04 ± 7.23 26.80 ± 6.08  
 PANSS—Total 72.19 ± 15.01 55.77 ± 14.26  
 CGI-S (median; range; min; max) 5; 3; 4; 7 4; 3; 3; 6  
 GAF 46.22 ± 10.45 59.90 ± 10.35  
 PSP 52.27 ± 14.80 62.27 ± 10.85  
Sample with PANSS at both timepoints (N = 30)
 PANSS—Positive 18.00 ± 6.17 13.57 ± 4.85 T(29) = 6.68; P < .01
 PANSS—Negative 18.30 ± 7.17 15.37 ± 6.19 T(29) = 3.47; P < .01
 PANSS—General 34.03 ± 7.09 26.80 ± 6.08 T(29) = 7.06; P < .01
 PANSS—Total 70.33 ± 15.51 55.77 ± 14.26 T(29) = 7.71; P < .01
 CGI-S (median; range; min; max) 5; 3; 4; 7 4; 3; 3; 6 Z = 4.36; P < .01
 GAF 47.13 ± 10.72 59.90 ± 10.35 T(29) = 5.92; P < .01
 PSP 52.97 ± 15.33 62.27 ± 10.85 T(29) = 3.64; P < .01
Note: Values are provided as mean ± SD unless otherwise stated. CGI-S, Clinical Global Impression- Schizophrenia; GAF, Global As-
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only been supported by indirect evidence.30,41–43 In this study, 
we examined glutamate levels in the ACC and caudate in 
patients with TRS before and after 12 weeks of switching 
to clozapine treatment. We found that reductions in gluta-
mate levels in the caudate over this period, and that this re-
duction was associated with improvements in symptoms. In 
contrast, there was no change in glutamatergic metabolites 
in the ACC. Secondary findings included observations that 
ACC glutamate was higher in clozapine naïve than re-trial 
participants, and in those who had consumed alcohol in 
the last week, and that caudate glutamate at baseline was 
higher in patients who were also taking an antidepressant 
medication. Overall, our main findings indicate that gluta-
mate reductions in the caudate, but not ACC, occur over 
the first months of clozapine treatment.
We hypothesized that clozapine would reduce ACC glu-
tamate levels, on the basis of preclinical research,19–21 and 
because the elevations ACC glutamate levels which have 
been observed in patients who have responding poorly to 
antipsychotics4,5,7,8 are not apparent in patients who are 
taking and have responded to clozapine.9,10 Contrary to 
this hypothesis, however, we did not observe reductions 
in ACC glutamate over 12 weeks of clozapine treatment, 
suggesting ACC glutamate levels are relatively stable over 
the initial months following clozapine initiation. It should 
be noted that previous cross-sectional studies of patients 
who were taking clozapine included participants who were 
already stabilized on clozapine therapy for several years.9,10 
Although the number of patients in our study who had 
taken clozapine previously was small, this subsample had 
lower ACC glutamate at baseline compared to those who 
were clozapine naïve. This could indicate that reductions 
in ACC glutamate metabolites might be observed after 
longer-term clozapine exposure. A second interpretation 
is that reductions in ACC glutamate are only observed in 
patients who have minimal symptom severity after cloza-
pine treatment. In the study of Iwata,10 ACC Glx did not 
differ between healthy volunteers and clozapine-treated 
patients with CGI-S and positive symptom scores of mild 
or less. While on average symptoms improved during our 
study, 83% (25/30) of participants still had CGI-S scores 
of ≥4 (moderate severity) at 12 weeks, so were relatively 
more unwell.
In the caudate, glutamate reduced over 12 weeks of clo-
zapine treatment, and this reduction correlated with the 
degree of symptomatic improvement. Reductions in glu-
tamate metabolites in the caudate are also observed over 
4 weeks of antipsychotic treatment in first-episode psy-
chosis.13 The caudate nucleus modulates information flow 
through corticostriatal loops to control cognitive and emo-
tional behavior.44 It is one of the major regions implicated 
in schizophrenia and in the action of dopamine D2 receptor 
antagonist antipsychotics.45,46 Clozapine could decrease 
caudate glutamate levels via its interactions with multiple 
receptor subtypes in cortical as well as subcortical regions47 
as well as potentially through more direct effects on the 
glutamatergic system.24,48–51 Given evidence for cortical 
abnormalities in TRS,52 studies examining corticostriatal 
connectivity during clozapine treatment would be useful 
to investigate these mechanisms further. As the 1H-MRS 
signal includes all MR-visible glutamate in the voxel, future 
pharmacological studies in animals combining 1H-MRS 
with invasive techniques to examine neurotransmission 
may provide further mechanistic information.
Table 3. Glutamatergic Metabolites in the Anterior Cingulate Cortex and Right Caudate at Baseline and After 12 Weeks of Clozapine in 
Participants With Treatment-Resistant Schizophrenia
Anterior Cingulate Cortex
Metabolite Baseline 12 Weeks Repeated Measures ANOVA
Total sample
 Glucorr 14.43 ± 2.41 (35) 15.46 ± 3.68 (26)  
 Glxcorr 19.94 ± 4.42 (35) 21.40 ± 5.57 (26)  
Completed sample
 Glucorr 14.77 ± 1.99 (24) 15.15 ± 3.58 (24) F (1,23) = 0.02, P = .59
 Glxcorr 21.05 ± 3.95 (24) 21.15 ± 5.68 (24) F (1,23) = 0.01, P = .93
 Right Caudate Nucleus 
Metabolite Baseline 12 Weeks  
Total sample
 Glucorr 12.08 ± 3.69 (34) 10.85 ± 1.58 (25)  
 Glxcorr 17.39 ± 5.56 (34) 14.90 ± 2.81 (25)  
Completed sample
 Glucorr 11.66 ± 2.00 (23) 10.73 ± 1.56 (23) F (1,22) = 7.61, P = .01
 Glxcorr 16.34 ± 3.75 (22) 14.78 ± 2.96 (22) F (1,21) = 4.73, P = .04
Note: Data is provided for the total number of subjects in which 1H-MRS was available each timepoint (Total sample) and for the sample 
who completed 1H-MRS at both timepoints (Completed Sample). Data are presented as mean ± SD (n). Glu, Glutamate; Glx, Gluta-
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A secondary and exploratory finding was that ACC 
glutamate was elevated in patients who reported con-
suming alcohol in the week prior to imaging, compared 
to those who did not. We are not aware of  previous 
research examining the effects of  alcohol intake on 
brain glutamate levels in patients with schizophrenia 
Fig. 1. Values in individual participants for Glutamate (Glucorr) and Glx (Glxcorr, glutamate plus glutamine) in the anterior cingulate 
cortex (ACC) and right caudate before and 12 weeks after switching to clozapine (left). The right column presents data as percentage 
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specifically. 1H-MRS studies in alcohol use disorder have 
reported increases in ACC glutamate during initial (24 
hour) withdrawal but reductions during drinking or ex-
tended abstinence.53–55 We excluded participants meeting 
the criteria for current substance dependence, as is 
common within schizophrenia neuroimaging studies. 
Our findings indicate that a more detailed analysis of 
the potential effects of  alcohol intake may be warranted, 
including intake below threshold levels for dependence. 
Similarly, the observation that caudate glutamate levels 
were higher in patients who were taking an antidepres-
sant highlights the importance of  considering potential 
influences of  concomitant medications. Nonetheless, 
our main findings of  no change in ACC glutamate and a 
reduction in caudate glutamate over clozapine treatment 
did not change when alcohol or antidepressant use were 
included as variables in the respective analyses.
Strengths of our study include the longitudinal de-
sign and our ability to recruit a relatively unwell patient 
group at the time of clozapine initiation. Our study had 
provision to include patients who lacked mental capacity 
to consent, in order to aid the generalizability of the re-
search to the clinical population. However, a significant 
proportion of the total sample were unable or declined 
to participate in MRI. This may impact on the general-
izability of the MRI study, including potentially biasing 
results towards less unwell TRS patients who may also 
have been more likely to respond to clozapine. As par-
ticipants had significant illness and clozapine is the only 
recommended antipsychotic for TRS, we did not inves-
tigate the effects of clozapine on glutamate in compar-
ison to placebo or an alternative active compound. These 
comparisons would be required to specifically attribute 
the reductions in symptoms or caudate glutamate levels 
to clozapine treatment rather than nonspecific aspects of 
study participation. A general limitation of 1H-MRS at 
3 Tesla is that the glutamate signal has an estimated con-
tamination by glutamine, albeit of <10%, and that glu-
tamine alone cannot be reliably estimated.4,56 Findings 
should also be interpreted in the context that 1H-MRS 
measures the total amount of intracellular glutamate, 
and the voxels include contributions from gray matter, 
white matter, and CSF. High bandwidth Very Spatially 
Selective Outer Volume Suppression pulses were used to 
suppress signal from outside the voxel, which may have 
led to underestimation of the unsuppressed water peak 
and overestimation of metabolite concentrations.57
In summary, the main finding of this study is that 1H-
MRS measures of glutamate metabolites in the caudate 
were reduced over 12 weeks of clozapine treatment and 
that this was associated with symptom reduction in TRS. 
In contrast, ACC glutamate was not significantly altered by 
clozapine over the observation period. Future studies could 
examine whether reductions in ACC glutamate occur over 
a longer period of clozapine treatment and the relationship 
with clinical outcome and could also examine corticostriatal 
connectivity to provide deeper mechanistic insight.
Supplementary Material
Supplementary material is available at Schizophrenia 
Bulletin online.
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